David  Weill net worth and biography

David Weill Biography and Net Worth

Director of TransMedics Group
David Weill is the Director of TransMedics Group.

What is David Weill's net worth?

The estimated net worth of David Weill is at least $1.72 million as of December 3rd, 2025. Weill owns 12,134 shares of TransMedics Group stock worth more than $1,722,543 as of January 14th. This net worth evaluation does not reflect any other assets that Weill may own. Learn More about David Weill's net worth.

How do I contact David Weill?

The corporate mailing address for Weill and other TransMedics Group executives is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. TransMedics Group can also be reached via phone at (978) 552-0900 and via email at [email protected]. Learn More on David Weill's contact information.

Has David Weill been buying or selling shares of TransMedics Group?

David Weill has not been actively trading shares of TransMedics Group during the past quarter. Most recently, David Weill sold 5,000 shares of the business's stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $138.64, for a transaction totalling $693,200.00. Following the completion of the sale, the director now directly owns 12,134 shares of the company's stock, valued at $1,682,257.76. Learn More on David Weill's trading history.

Who are TransMedics Group's active insiders?

TransMedics Group's insider roster includes John Carey (VP), Nicholas Corcoran (Insider), Laura Damme (VP), Stephen Gordon (CFO), Waleed Hassanein (CEO), Gerardo Hernandez (CFO), Edwin Kania, Jr. (Director), Tamer Khayal (Insider), Miriam Provost (VP), Anil Ranganath (Insider), and David Weill (Director). Learn More on TransMedics Group's active insiders.

Are insiders buying or selling shares of TransMedics Group?

In the last year, insiders at the sold shares 8 times. They sold a total of 25,480 shares worth more than $3,310,247.26. The most recent insider tranaction occured on December, 4th when CFO Gerardo Hernandez sold 920 shares worth more than $128,450.40. Insiders at TransMedics Group own 7.0% of the company. Learn More about insider trades at TransMedics Group.

Information on this page was last updated on 12/4/2025.

David Weill Insider Trading History at TransMedics Group

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/3/2025Sell5,000$138.64$693,200.0012,134View SEC Filing Icon  
5/23/2025Sell732$123.88$90,680.1612,134View SEC Filing Icon  
5/29/2024Sell1,193$141.65$168,988.4510,732View SEC Filing Icon  
5/10/2024Sell2,500$129.82$324,550.0011,193View SEC Filing Icon  
8/29/2023Buy2,500$62.00$155,000.0013,693View SEC Filing Icon  
2/27/2023Sell5,934$76.69$455,078.4610,000View SEC Filing Icon  
11/10/2022Sell21,645$56.00$1,212,120.0013,500View SEC Filing Icon  
11/11/2019Buy10,000$17.00$170,000.0010,000View SEC Filing Icon  
See Full Table

David Weill Buying and Selling Activity at TransMedics Group

This chart shows David Weill's buying and selling at TransMedics Group by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

TransMedics Group Company Overview

TransMedics Group logo
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Read More

Today's Range

Now: $141.96
Low: $136.00
High: $142.95

50 Day Range

MA: $130.01
Low: $113.40
High: $150.42

2 Week Range

Now: $141.96
Low: $55.00
High: $156.00

Volume

921,512 shs

Average Volume

593,742 shs

Market Capitalization

$4.85 billion

P/E Ratio

57.47

Dividend Yield

N/A

Beta

2.03